Centers of Excellence for Translational Research (CETR) (U19 Clinical Trial Not Allowed)
ID: 351471Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $5M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351471

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-065.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Dec 13, 2023 12:00 AM
  4. 4
    Due Apr 29, 2024 12:00 AM
Description

The National Institutes of Health (NIH) has posted a grant opportunity titled "Centers of Excellence for Translational Research (CETR) (U19 Clinical Trial Not Allowed)". This opportunity falls under the category of Health and is a Cooperative Agreement. The grant does not require cost sharing or matching.

The purpose of this grant is to solicit applications from single institutions or a consortium of institutions to participate in the Centers for Excellence in Translational Research (CETR) program. The program aims to support multidisciplinary translational research centers focused on generating, validating, and advancing medical countermeasures against bacteria or fungi listed in the grant notice with known and emerging resistance to current therapies.

The grant has an award ceiling of $5,000,000 and the closing date for applications is April 29, 2024. For more information and to apply, interested parties can visit the following website: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-065.html.

For any inquiries or additional information, please contact NIH Grants Information at grantsinfo@nih.gov.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
RFA-AI-23-065-Full-Announcement.html
4/10/2024
Similar Opportunities
Center of Excellence for Systems Modeling of Infection and Immunity across Biological Scales (U54 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Center of Excellence for Systems Modeling of Infection and Immunity across Biological Scales (U54 Clinical Trial Not Allowed)". This grant aims to support the establishment of a Center of Excellence (CoE) that will coordinate the research community of infectious and immune-mediated disease (IID) computational modelers and advance IID modeling research across biological scales. The CoE will include three coordinating cores and two research projects to advance and integrate bridge models across scales in the context of IID, including HIV/AIDS. The main objective of the CoE is to accelerate multi-scale model development, sharing and re-use, and support collaboration to benefit the entire IID research community. The grant does not require cost sharing or matching requirements and falls under the category of funding activity for health. It is a cooperative agreement type of funding instrument. The opportunity is open to "Other Eligible Applicants" which include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. However, Non-domestic (non-U.S.) Entities (Foreign Organization) and non-U.S. components of U.S. Organizations are not eligible to apply. The grant opportunity has a closing date of July 30, 2024, and the last updated date was March 13, 2024. The description of the grant provides detailed information on the purpose and requirements of the CoE. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov. More information about the grant can be found at the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-077.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-077.html).
IDeA Clinical and Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "IDeA Clinical and Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional)". This grant aims to expand the capacity for clinical and translational research in IDeA-eligible states/jurisdictions and enhance the competitiveness of investigators to obtain extramural funding for such research. The purpose of this funding opportunity is to provide cooperative agreement support for statewide and/or interstate regional networks. These networks will focus on three main objectives: 1. Supporting the development and/or enhancement of infrastructure and human resources required to address clinical and translational research needs in IDeA-eligible states/jurisdictions. 2. Strengthening clinical and translational research that addresses the broad spectrum of health challenges faced by populations in IDeA-eligible states/jurisdictions. 3. Fostering and coordinating collaboration in clinical and translational research within an IDeA-CTR network and with other institutions. The grant does not require cost sharing or matching and falls under the category of funding activity for health. The maximum award ceiling for this grant is $1,500,000. The opportunity is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territories or Possessions. Non-domestic (non-U.S.) entities and components are not eligible to apply. The closing date for this grant opportunity is October 9, 2025, and the archive date is November 14, 2025. For more information and to apply, interested parties can visit the following website: [IDeA Clinical and Translational Research Development (CTR-D) Award](http://grants.nih.gov/grants/guide/pa-files/PAR-23-257.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.
CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)". This grant aims to support translational exploratory/developmental research projects that advance the discovery of novel treatment strategies, specifically medical countermeasures (MCMs), for addressing serious morbidity and mortality caused by acute exposure to highly toxic chemical threats. Chemical threats encompass toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and ultra-potent synthetic (UPS) opioids. The grant supports translational research that involves preliminary efficacy and/or early preclinical development studies to discover and validate novel molecular entities or biologics as candidate MCMs. In addition to novel agents, the grant also encourages the exploration of new treatment strategies, such as repurposing already FDA-approved products or combinations of interventions based on established mechanisms of action. Projects funded by this grant are expected to generate preliminary data that will facilitate the development of competitive applications for further support from the NIH CounterACT Cooperative Agreement program and other related initiatives. The grant does not require cost sharing or matching requirements and falls under the category of funding activity related to health. The opportunity is posted on grants.gov and is classified as discretionary. The CFDA number associated with this grant is 93.867. The eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territories or Possessions. Non-domestic (non-U.S.) entities (foreign organizations) and non-domestic components of U.S. organizations are not eligible to apply. The grant has a closing date of May 30, 2025, and an archive date of July 5, 2025. The award ceiling for this grant is $275,000. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/pa-files/PAR-23-139.html](http://grants.nih.gov/grants/guide/pa-files/PAR-23-139.html). For any inquiries, individuals can contact NIH Grants Information at grantsinfo@nih.gov.
CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a federal grant opportunity titled "CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)". This grant aims to support the early-stage development of therapeutics that can mitigate the adverse health effects resulting from toxic chemical exposure. The service/item being procured is the development of therapeutics to combat chemical threats, which include toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. These chemical threats encompass specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The grant seeks to validate therapeutic targets and conduct preclinical characterization of lead compounds. The UG3 phase of the grant supports target validation and characterization of initial lead compound(s), while the UH3 phase focuses on candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. By the end of the funding period, projects are expected to deliver at least one well-characterized therapeutic candidate. The grant is a cooperative agreement and falls under the category of funding activity related to health. There is no cost sharing or matching requirement for this grant opportunity. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. territories or possessions. Non-domestic (non-U.S.) entities and components are not eligible to apply. The grant has a closing date of October 17, 2024, and an award ceiling of $350,000. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/pa-files/PAR-22-209.html](http://grants.nih.gov/grants/guide/pa-files/PAR-22-209.html). For any inquiries, the NIH OER Webmaster can be contacted at OERWebmaster03@od.nih.gov.
Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed)". This grant aims to support the development of highly innovative technologies that address barriers in translational science, specifically for therapeutic development. The grant will fund early-stage proof of concept, high-risk, and potentially high-reward studies for feasibility and exploratory technology development. The goal is to improve the efficiency of therapeutic development and ultimately provide more treatments to people more quickly. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and Historically Black Colleges and Universities (HBCUs), among others. Non-domestic entities and components are not eligible to apply. The grant has a maximum award ceiling of $275,000. The deadline for applications is June 19, 2025. For more information and to apply, visit the NIH grants website at [http://grants.nih.gov/grants/guide/pa-files/PAR-23-177.html](http://grants.nih.gov/grants/guide/pa-files/PAR-23-177.html).